Apply to Graduate School | Library | Jobs & Volunteers | Visitor Information | Department Index | News      
Center for Human Genomics at Wake Forest University School of Medicine

David M. Herrington, MD, MHS
Professor, Internal Medicine (Cardiology)
Associate in Public Health Sciences

Davidson College, BS, 1979
University of North Carolina-Chapel Hill School of Medicine, MD, 1983
The Johns Hopkins University School Hygiene and Public Health, MHS, 1989

Research Interests

Dr. Herrington's focus is on the role of estrogen in the pathogenesis of coronary heart disease in postmenopausal women. Of late, he has investigated genetic approaches to understanding differential responses to estrogen agonists (hormone replacement therapy or selective estrogen receptor modulators), in collaboration with colleagues in the Human Genomics Center. This promising avenue is now a major area of Dr. Herrington's research activity, and he holds three R01 awards to pursue research questions in this area.

Selected Publications: Journal Articles

Seely EW, Brosnihan KB, Jeunemaitre X, Okamura K, Williams GH, Hollenberg NK, Herrington DM. Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women. Clin Endocrinol (Oxf). 2004 Mar;60(3):315-21.

Tansavatdi K, McClain B, Herrington DM. [The effects of smoking on estradiol metabolism] Minerva Ginecol. 2004 Feb;56(1):105-14. In Italian.

Waters DD, Gordon D, Rossouw JE, Cannon RO 3rd, Collins P, Herrington DM, Hsia J, Langer R, Mosca L, Ouyang P, Sopko G, Stefanick ML; National Heart, Lung and Blood Institute; American College of Cardiology Foundation. Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002 : Section 4: lessons from hormone replacement trials. Circulation. 2004 Feb 17;109(6):e53-5.

Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C; TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004 Jan 15;93(2):154-8.

Sherman AM, Shumaker SA, Sharp P, Reboussin DM, Kancler C, Walkup M, Herrington DM. No effect of HRT on health-related quality of life in postmenopausal women with heart disease. Minerva Ginecol. 2003 Dec;55(6):511-7.

Daniel KR, Herrington DM. Statin therapy in the heart and estrogen/ progestin replacement study. Minerva Ginecol. 2003 Jun;55(3):209-15.

Herrington DM, Kesler K, Reiber JC, Davis W, Brown WV, Helms R, Mallon SM, Raines J. Arterial compliance adds to conventional risk factors for prediction of angiographic coronary artery disease. Am Heart J. 2003 Oct;146(4):662-7.

Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res. 2003 Oct 1;59(4):812-23.

Nieto FJ, Herrington DM, Redline S, Benjamin EJ, Robbins JA. Sleep apnea and markers of vascular endothelial function in a large community sample of older adults. Am J Respir Crit Care Med. 2004 Feb 1;169(3):354-60.

Herrington DM, Howard TD. From presumed benefit to potential harm--hormone therapy and heart disease. N Engl J Med. 2003 Aug 7;349(6):519-21.

Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, Polak JF, Sutton-Tyrrell K, Herrington DM, Price TR, Cushman M. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003 Jul 15;108(2):166-70.

Sherman AM, Shumaker SA, Kancler C, Zheng B, Reboussin DM, Legault C, Herrington DM; ERA Trial Investigators. Baseline health-related quality of life in postmenopausal women with coronary heart disease: the Estrogen Replacement and Atherosclerosis (ERA) trial. J Womens Health (Larchmt). 2003 May;12(4):351-62.

Willens HJ, Davis W, Herrington DM, Wade K, Kesler K, Mallon S, Brown WV, Reiber JH, Raines JK. Relationship of peripheral arterial compliance and standard cardiovascular risk factors. Vasc Endovascular Surg. 2003 May-Jun;37(3):197-206.

Redberg RF, Vogel RA, Criqui MH, Herrington DM, Lima JA, Roman MJ.
34th Bethesda Conference: Task force #3--What is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis? J Am Coll Cardiol. 2003 Jun 4;41(11):1886-98.

Herrington DM, Howard TD. ER-alpha variants and the cardiovascular effects of hormone replacement therapy. Pharmacogenomics. 2003 May;4(3):269-77.

Abdelhamed AI, Reis SE, Sane DC, Brosnihan KB, Preli RB, Herrington DM. No effect of an L-arginine-enriched medical food (HeartBars) on endothelial function and platelet aggregation in subjects with hypercholesterolemia. Am Heart J. 2003 Mar;145(3):E15.

Herrington DM. Role of estrogen receptor-alpha in pharmacogenetics of estrogen action. Curr Opin Lipidol. 2003 Apr;14(2):145-50.

Herrington DM, Klein KP. Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findings. Atherosclerosis. 2003 Feb;166(2):203-12.

Herrington DM. Hormone replacement therapy and heart disease: replacing dogma with data. Circulation. 2003 Jan 7;107(1):2-4. No abstract available.

Klein KP, Herrington DM. Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women. Medscape Womens Health. 2002 Sep-Oct;7(5):2. Review. No abstract available.

Byington RP, Furberg CD, Herrington DM, Herd JA, Hunninghake D, Lowery M, Riley W, Craven T, Chaput L, Ireland CC, Applegate WB. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1692-7.

Herrington DM, Vittinghoff E, Lin F, Fong J, Harris F, Hunninghake D, Bittner V, Schrott HG, Blumenthal RS, Levy R. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 2002 Jun 25;105(25):2962-7.

Herrington DM, Vittinghoff E, Howard TD, Major DA, Owen J, Reboussin DM, Bowden D, Bittner V, Simon JA, Grady D, Hulley SB. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):1012-7.

Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation. 2002 Apr 23;105(16):1879-82.

Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, Meyers DA, Bleecker ER. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002 Mar 28;346(13):967-74.

Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002 Jul 3;288(1):49-57.